Deal Intelligence
Biopharma Deal Insights
Data-driven analysis of biopharma deal structure, licensing benchmarks, and valuation trends — backed by 1,900+ real transactions.
Biopharma Deal Benchmarks 2026
Comprehensive benchmarks across 13 therapeutic areas with phase-by-phase economics.
ADC vs Bispecific Deal Benchmarks
Head-to-head comparison of ADC and bispecific antibody deal structures and valuations.
Oncology Upfront Payment Benchmarks
Upfront payment trends in oncology licensing deals by phase and modality.
Pharma Licensing Royalty Rates
Royalty rate benchmarks across therapeutic areas, phases, and deal types.
Deal Terms by Therapeutic Area
How deal economics vary across oncology, neurology, immunology, and 9 other TAs.
Phase 2 Milestone Payment Benchmarks
Development, regulatory, and commercial milestone structures at Phase 2.
Preclinical Asset Valuation
How to value and structure licensing deals for preclinical-stage assets.
European Biotech Licensing Deals
Deal structure and valuation trends for European biotech out-licensing.
Asia-Pacific Out-Licensing
China-to-West licensing surge and APAC deal economics.
Israel Biotech Deal Benchmarks
Israeli biotech licensing deal data and partnership trends.
Biopharma Deal Valuation Methods
rNPV, Monte Carlo, real options, and comparable deal approaches compared.
Biotech Out-Licensing Deal Terms
2025-2026 deal structure trends for biotech out-licensing transactions.
Q1 2026 Deal Benchmarks
Quarterly update on deal activity, upfront trends, and market shifts.
Biopharma Deal Benchmarking Tools
Comparison of deal benchmarking platforms and methodologies.
How Much Is My Biotech Asset Worth?
A practical guide to valuing biotech assets for licensing and acquisition.
Licensing vs Acquisition Deal Terms
When to license and when to sell — deal economics compared.
Phase 2 vs Phase 3 Deal Economics
The Phase 2 inflection point and how deal terms shift at Phase 3.
Deal Committee Presentation Guide
How to build a board-ready deal analysis for investment committees.
Pharma Partner Identification Guide
Data-driven approach to finding the right licensing partner.
rNPV vs DCF Biotech Valuation
When to use risk-adjusted NPV vs discounted cash flow in biotech deals.
Biotech Fundraising Deal Benchmarks
Fundraising and partnership deal economics for biotech companies.